Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Rapid Impact Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Metabolism Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Spotlight on Genomic Analysis of Rare and Understudied Cancers
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Research
Molecular Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Rapid Impact Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Metabolism Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Spotlight on Genomic Analysis of Rare and Understudied Cancers
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Highlights

Highlights of This Issue

DOI:  Published March 2016
  • Article
  • Info & Metrics
  • PDF
Loading

Aspirin and Salicylic Acid Down-regulate Cyclin A2/CDK2

Dachineni et al. Page 241

The evidence that aspirin prevents cancer is compelling; however, the underlying mechanism leading to its anti-cancer effect is enigmatic. In this research article, cyclin A2 and CDK2 are demonstrated to be novel targets of aspirin and its primary metabolite, salicylic acid. Both therapeutic agents caused down-regulation of cyclin A2 and CDK2, at the protein and mRNAs levels, in a diverse panel of cancer cells and resulted in a reduction in CDK2 activity. Importantly, it is also demonstrated that CDK2 is a novel salicylic acid binding protein. These results show that the anti-cancer effects of aspirin occur through down-regulation of cell cycle regulatory proteins.

Targeting the Adaptive Hypoxic Response in Multiple Myeloma

Mysore et al. Page 253

Multiple myeloma resides in a hypoxic environment and shows signs of an induced hypoxic response that contributes to tumorigenesis and tumor drug resistance. Targeting this adaptive hypoxic response would have important ramifications for treating this disease. To test this, Mysore and colleagues used a Pyrrole-Imidazole polyamide that can displace a major regulator of hypoxic response, HIF1, from its DNA-binding site. Evidence shows that the polyamide suppressed growth of multiple myeloma xenografts in mice and inhibited the hypoxic response in vitro and in vivo; thus, revealing the therapeutic utility of these molecules in the treatment of multiple myeloma.

KRAS Regulated miR-31 Modulates Invasion Migration

Kent et al. Page 267

Pancreatic cancer is a deadly and highly metastatic disease frequently harboring activating mutations in the KRAS oncogene. MicroRNAs (miRs) are important regulators of gene expression with an established role in cancer pathogenesis. Here, miR-31 is identified as a transcriptional target of the RAS-MAPK signaling pathway. The miR-31 host gene promoter is activated by the transcription factor ELK1. Enforced expression of miR-31 enhanced invasion-migration of pancreatic cancer cells via down regulation of the miR-31 target RASA1 and activation of RHOA. These results implicate miR-31 as a novel effector in the RAS-transformation program and demonstrate a mechanism for the metastatic behavior of pancreatic cancer.

Cancer-associated Fibroblasts Regulate Collagen Cross-linking

Pankova et al. Page 287

Cancer-associated fibroblasts (CAFs) are a vital cellular component of the tumor microenvironment (TME) and are a recognized source of intratumoral collagen. This study is important because it shows that CAFs not only produce collagen but also regulate the types of cross-links that form between collagen strands and contribute to the biomechanical properties of tumor stroma. Mechanistically, this activity of CAFs was mediated by lysyl hydroxylase 2 (PLOD2/LH2), which strengthens the growing body of evidence that targeting LH2 has the potential to suppress the growth and metastasis of tumors in patients.

  • ©2016 American Association for Cancer Research.
Next
Back to top
Molecular Cancer Research: 14 (3)
March 2016
Volume 14, Issue 3
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Highlights of This Issue
(Your Name) has forwarded a page to you from Molecular Cancer Research
(Your Name) thought you would be interested in this article in Molecular Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Highlights of This Issue
Mol Cancer Res March 1 2016 (14) (3) 239;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Highlights of This Issue
Mol Cancer Res March 1 2016 (14) (3) 239;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Aspirin and Salicylic Acid Down-regulate Cyclin A2/CDK2
    • Targeting the Adaptive Hypoxic Response in Multiple Myeloma
    • KRAS Regulated miR-31 Modulates Invasion Migration
    • Cancer-associated Fibroblasts Regulate Collagen Cross-linking
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Selected Articles from This Issue
  • Selected Articles from This Issue
  • Selected Articles from This Issue
Show more Highlights
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Rapid Impact Archive
  • Meeting Abstracts

Information for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCR

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Research
eISSN: 1557-3125
ISSN: 1541-7786

Advertisement